What's Happening?
Brightseed, a company focused on uncovering the 'dark matter of nutrition,' has introduced Hummingbird, an agentic AI product designed to enhance its Forager bioactives discovery platform. Founded in 2017, Brightseed has developed a comprehensive database
of 21 million plant-based compounds linked to biological targets. The Forager platform predicts which compounds may offer specific health benefits and identifies optimal sourcing or production methods. Hummingbird aims to streamline the process from discovery to development by integrating AI, allowing partners to quickly access detailed insights and recommendations. This innovation addresses previous bottlenecks in scaling the platform, enabling faster and more efficient development of health products. Brightseed has already onboarded two customers since February and is in the process of contracting with several more.
Why It's Important?
The launch of Hummingbird represents a significant advancement in the field of bioactives discovery and development. By leveraging AI, Brightseed is able to provide more actionable insights to its partners, potentially accelerating the development of new health products. This could have a substantial impact on the nutrition, health, and wellness industries, allowing companies to bring innovative products to market more quickly. The ability to efficiently identify and develop bioactive compounds could lead to breakthroughs in addressing various health issues, benefiting consumers and potentially reducing healthcare costs. Additionally, the integration of AI into this process highlights the growing importance of technology in transforming traditional industries.
What's Next?
Brightseed plans to continue expanding its Hummingbird platform by rolling out new agents associated with different tasks on a quarterly basis. This includes a 'white space' agent currently in alpha testing, with a claims agent and other specialized agents to follow. The company aims to deploy a new agent at least once every quarter, further enhancing the platform's capabilities. As more companies adopt Hummingbird, it is likely that the platform will continue to evolve, incorporating feedback and expanding its dataset. This ongoing development could lead to even more efficient and effective bioactives discovery and commercialization processes.
